Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GSK eyes life after a patent cliff

This article was originally published in The Tan Sheet

Executive Summary

GlaxoSmithKline is shifting "from being a blockbuster-dependent" company that relies on a single patented drug for a bulk of its revenue to a "blockbuster-ready" firm with a well-diversified portfolio that provides protection if the next big drug comes too late to offset generic competition for the current top-seller, CEO Andrew Witty says. At Cowen & Co.'s Health Care Conference March 17 in Boston, Witty said GSK is seeking diversity rather than the next blockbuster drug to "diminish the possibility of simply going back to another patent cliff," like the one it fell off last year when it lost exclusivity for several prescription drugs. GSK will invest in multiple small prescription drugs and seeks bolt-on acquisitions of vaccines and brands in "the consumer emerging market" to reduce the impact of any one patent expiry, Witty said (1"The Tan Sheet" Feb. 9, 2009, p. 9)

You may also be interested in...



GSK Invests In Consumer Unit To Overcome Generic Threat, Low Alli Sales

GlaxoSmithKline expects to overcome increasing generic competition by growing its consumer health business and investing in emerging markets, rather than by pursuing a mega-merger like Pfizer-Wyeth

The Factory Floor: Biocon Celebrates Malaysian Insulin Plant Clearance

Biocon has reported FDA clearance for its Malaysian insulin facility, while Lupin and Xellia have also received plant approvals. Meanwhile, Alembic has seen mixed fortunes, receiving both Form 483 observations and an EIR.

Lannett Rolls Out US Adderall XR Rival

Lannett has begun marketing a US rival to Adderall XR through a partnership with Elite and SunGen. But the product will face competition from a range of other generics.

Topics

UsernamePublicRestriction

Register

PS102734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel